You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Go to Close Top

Dosage & device

A modern delivery system 3 - 6

Avamys gentle mist easy to use device

In the preference study with FPNS (Meltzer EO, et al. 2008) the overall incidence of AEs with FF was 2% or 3 events: dizziness, headache, nasal congestion. 6

Stays where it sprays 1

Avamys Spray Comparison video

Video player requires JavaScript enabled. You can download this video here:

Watch a video comparison of Avamys spray viscosity versus 2 competitor INS's devices

Avamys is preferred over MFNS* 7 8

  • Several perceived sensory attributes of FFNS were rated significantly superior to MFNS 7
  • FFNS may contribute to enhanced treatment outcomes in AR patients due to improved treatment adherence 7

Overall, significantly more patients preferred FFNS over MFNS, p<0.001 8

Patient preference 56%
Patient preference 32%

Avamys provides improved experience vs MFNS 8

Less drip down nose

Less drip down nose
or throat

(p<0.05 and p<0.001, respectively)

Less irritation

Less irritation 8


More soothing

More soothing 8


Overall 5 patients (2%) reported AEs with FFNS and 13 patients (4%) with MFNS. Few common AEs were reported: rhinorrhoea, nasal discomfort, cough. No severe safety issues were identified during the study. 8

How to use device

Download Now

How to use device

Order hard copies now

*Multicentre, randomised, double-blind, cross-over study where patient (n=300) preferences were determined by using three questionnaires
(Overall Preference, Immediate Attributes and Delayed Attributes).
AE: Adverse event; AR: Allergic rhinitis; FFNS: Fluticasone furoate nasal spray; FPNS: Fluticasone propionate nasal spray; MFNS: Mometasone furoate nasal spray.


  1. Vasar M, Houle PA, Douglass JA, et al. Fluticasone furoate nasal spray: Effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc. 2008;29(3);313-321.
  2. Avamys SmPC available on last accessed May 2019
  3. Berger WE, Godfrey JW, Slater AL. Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance. Expert Opin Drug Deliv. 2007;4(6):689-701.
  4. Berger WE, Godfrey JW, Grant AC, et al. Fluticasone furoate (FF) nasal spray: development of a next-generation delivery system for allergic rhinitis [abstract no. 907]. J Allergy Clin Immunol. 2007;119:S231.
  5. Godfrey JW, Grant AC, Slater AL. Fluticasone Furoate (FF) Nasal spray-ergonomic considerations for a next generation delivery system. J Allergy Clin lmmunol. 2007;119(Suppl. 1):S230.
  6. Meltzer EO, Stahlman JE, Leflein J, et al. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: A randomized, multicenter, double-blind, single-dose, crossover study. Clin Ther. 2008;30(2):271-279.
  7. Yonezaki M, Akiyama K, Karaki M, et al. Preference evaluation and perceived sensory comparison of fluticasone furoate and mometasone furoate intranasal sprays in allergic rhinitis. Auris Nasus Larynx. 2016;43(3):292-297.
  8. Yanez A, Dimitroff A, Bremner P, et al. A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis. Allergy Rhinol. 2016;7(4):e183–e192.

Avamys is a registered trademark of the GlaxoSmithKline group of companies